Xerava(eravacycline)
Xerava (eravacycline) is a small molecule pharmaceutical. Eravacycline was first approved as Xerava on 2018-08-27. It is used to treat intraabdominal infections in the USA. It has been approved in Europe to treat bacterial infections and infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
Trade Name
FDA
EMA
Xerava
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Eravacycline dihydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XERAVA | Tetraphase Pharmaceuticals | N-211109 RX | 2018-08-27 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xerava | New Drug Application | 2024-12-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| intraabdominal infections | — | D059413 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ERAVACYCLINE DIHYDROCHLORIDE, XERAVA, TETRAPHASE PHARMS | |||
| 2028-08-27 | GAIN | ||
| 2023-08-27 | NCE | ||
HCPCS
Code | Description |
|---|---|
| J0122 | Injection, eravacycline, 1 mg |
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 1 | 3 | 1 | 1 | 7 |
| Bacterial infections | D001424 | — | A49 | 1 | — | — | 1 | 1 | 3 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Communicable diseases | D003141 | — | — | — | 1 | 3 | — | — | 4 |
| Intraabdominal infections | D059413 | — | — | — | 1 | 2 | — | — | 3 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | — | 2 | — | — | 2 |
| Appendicitis | D001064 | EFO_0007149 | K37 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hematologic neoplasms | D019337 | — | — | — | 1 | — | — | — | 1 |
| Neutropenia | D009503 | — | D70 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.9 | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 2 | 2 |
| Acinetobacter baumannii | D040981 | NCBITaxon_470 | — | — | — | — | — | 2 | 2 |
| Pulmonary infarction | D054060 | EFO_1001408 | — | — | — | — | — | 1 | 1 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Bacterial drug resistance | D024881 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Eravacycline |
| INN | eravacycline |
| Description | Eravacycline is a member of tetracyclines. |
| Classification | Small molecule |
| Drug class | antibiotics (tetracycline derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)c(NC(=O)CN5CCCC5)cc(F)c4C[C@H]3C[C@@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 1207283-85-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1951095 |
| ChEBI ID | — |
| PubChem CID | 54726192 |
| DrugBank | — |
| UNII ID | 07896928ZC (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xerava – Innoviva
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Xerava – La Jolla Pharmaceutical Company
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,315 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
110 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use